In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients

Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Feb 13, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to better understand the environment around solid tumors in patients with various types of cancer, including head and neck, urologic, lung, breast, and liver cancers. The researchers want to see how these tumors change when patients receive anti-cancer treatments, especially those developed by a company called Innate Pharma. By studying these changes, the trial aims to gather important information that could help create new treatments that use the body’s immune system to fight cancer more effectively.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of cancer that fits the study criteria. Before joining, you'll need to sign a consent form showing that you understand the study and agree to take part. The trial is not yet recruiting participants, so there will be more information to come. If you have any questions about your eligibility or what participating in the study involves, the research team will be happy to help you understand more about what to expect.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older
• • Histologic, cytologic or imaging confirmation of a malignancy in accordance with targeted indications
• • Written informed consent signed from subject prior to performing any protocol-related procedures
• Exclusion Criteria:
• • Use of any investigational agent within 14 days prior first visit;
• • Patient under guardianship/trusteeship or legally incapacitated person;
• • Patient unable to understand read and/or sign an informed consent;
• • Uncooperative or potentially non-compliant for the study or study procedures patient, or with foreseeable regular follow-up difficulties;
• • Patient without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme;
• • Patients who are known to be HIV positive